Trial Profile

An exploratory biomarker study in an investigator initiated phase II trial of atezolizumab in patients with relapsed/refractory NK/T-cell lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary)
Indications Extranodal NK-T-cell lymphoma
Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
Acronyms ATTACK
Sponsors Chugai Pharmaceutical

Most Recent Events

31 Mar 2022 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
30 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com